OUR STRATEGY

Performance against Strategy

OUR STRATEGY

Performance against Strategy

TESTING AND QUALITY

Aspiration

  • Provide quality testing in an efficient manner

Strategic Priorities

  • Harmonise quality standards to meet international benchmarks
  • SANBS products and services meet the quality control requirements at regulatory bodies and national standards to meet internal and external customer requirements

FY22 Highlights

  • Blood safety index maintained consistently above target
  • 100% SANAS Accreditation maintained

Contribution to Long-term Sustainable Value

Related Material
Matters

  • Regulatory landscape
  • Future changing world
  • Financial and organisational sustainability

TESTING AND QUALITY

Aspiration

  • Provide quality testing in an efficient manner

Strategic Priorities

  • Harmonise quality standards to meet international benchmarks
  • SANBS products and services meet the quality control requirements at regulatory bodies and national standards to meet internal and external customer requirements

FY22 Highlights

  • Blood safety index maintained consistently above target
  • 100% SANAS Accreditation maintained

Contribution to Long-term Sustainable Value

Related Material
Matters

  • Regulatory landscape
  • Future changing world
  • Financial and organisational sustainability

Reflecting on our performance against the 2021/2022 Scorecard and how we added value

Target achieved/exceeded New initiative on track against current plan (no concerns Improvements YOY No Concerns yet Below Target

Reflecting on our performance against the 2021/2022 Scorecard and how we added value

Target achieved/exceeded New initiative on track against current plan (no concerns Improvements YOY No Concerns yet Below Target

Below, we further unpack the various components of our performance against our iHEALTh strategy

Key Measured Initiatives

Below, we further unpack the various components of our performance against our iHEALTh strategy

Key Measured Initiatives

Blood safety index

Target

  • >=95%

IR 2021

  • 97.3%

Progress for FY22

  • 97.24%

target for 2022/2023

  • >=95%

Blood safety index

Target

  • >=95%

IR 2021

  • 97.3%

Progress for FY22

  • 97.24%

target for 2022/2023

  • >=95%

Accreditation

Target

  • 100% SANAS Accreditation

IR 2021

  • 100%

Progress for FY22

  • 100%

target for 2022/2023

  • 100% SANAS Accreditation

Accreditation

Target

  • 100% SANAS Accreditation

IR 2021

  • 100%

Progress for FY22

  • 100%

target for 2022/2023

  • 100% SANAS Accreditation

Meet ISO 9001 standards

Target

  • New project

IR 2021

Progress for FY22

  • Baseline audits conducted for support areas and gap analysis completed

target for 2022/2023

  • Fully compliant with ISO 9001 standards

Meet ISO 9001 standards

Target

  • New project

IR 2021

Progress for FY22

  • Baseline audits conducted for support areas and gap analysis completed

target for 2022/2023

  • Fully compliant with ISO 9001 standards

Meet SLA TAT for standard crossmatches

Target

  • >90% of standard crossmatches completed within agreed SLA TAT of 120 minutes

IR 2021

  • 81.83% of standard crossmatches completed within agreed SLA TAT of 120 minutes
  • The TAT for standard crossmatches is improving, primarily as a result of improved reporting

Progress for FY22

  • 83.2%
  • Staff shortages during Covid-19 Cutbacks cause delays Instrument breakdowns Instrument suppliers changed Some manual testing required which increased TAT

target for 2022/2023

  • >=90% of standard crossmatches completed within agreed SLA TAT of 120 minutes
  • Process improvements being considered
  • Moved to Testing and Quality on scorecard
  • Time and motion studies
  • Monitoring blood banks

Meet SLA TAT for standard crossmatches

Target

  • >90% of standard crossmatches completed within agreed SLA TAT of 120 minutes

IR 2021

  • 81.83% of standard crossmatches completed within agreed SLA TAT of 120 minutes
  • The TAT for standard crossmatches is improving, primarily as a result of improved reporting

Progress for FY22

  • 83.2%
  • Staff shortages during Covid-19 Cutbacks cause delays Instrument breakdowns Instrument suppliers changed Some manual testing required which increased TAT

target for 2022/2023

  • >=90% of standard crossmatches completed within agreed SLA TAT of 120 minutes
  • Process improvements being considered
  • Moved to Testing and Quality on scorecard
  • Time and motion studies
  • Monitoring blood banks

Turn-around time for units to become available for use

Target

  • 95%

IR 2021

  • 144%

Progress for FY22

  • 91.4%
  • BI reporting improved causing the value to drop

target for 2022/2023

  • >=95%
  • Software and hardware upgrades planned to improve sending of results

Turn-around time for units to become available for use

Target

  • 95%

IR 2021

  • 144%

Progress for FY22

  • 91.4%
  • BI reporting improved causing the value to drop

target for 2022/2023

  • >=95%
  • Software and hardware upgrades planned to improve sending of results

NAVIGATE TO:

NAVIGATE TO:

How can we help you?

Let's Connect

Head Office

  • 1 Constantia Boulevard Constantia Kloof, Roodepoort, 1709
  • (011) 761-9000
  • customerservice@sanbs.org.za

Main Links

Ⓒ 2022 - All Rights Are Reserved. SANBS Integrated Report. Created by Joshero (Pty) Ltd.

Head Office

  • 1 Constantia Boulevard Constantia Kloof, Roodepoort, 1709
  • (011) 761-9000
  • customerservice@sanbs.org.za

Main Links

Ⓒ 2022 - All Rights Are Reserved. SANBS Integrated Report. Created by Joshero (Pty) Ltd.